1. Tusseau, Maud, Lovšin, Ema, Samaille, Charlotte, Cimaz, Rolando, Belot, Alexandre. 2022. DNASE1L3 deficiency, new phenotypes, and evidence for a transient type I IFN signaling. In Journal of clinical immunology, 42, 1310-1320. doi:10.1007/s10875-022-01287-5. https://pubmed.ncbi.nlm.nih.gov/35670985/
2. Wang, W, Li, X L, Li, W D, Ma, M S, Song, H M. . [A monogenic lupus family caused by homozygous deletions of DNASE1L3 gene and literature review]. In Zhonghua er ke za zhi = Chinese journal of pediatrics, 60, 1276-1281. doi:10.3760/cma.j.cn112140-20220926-00839. https://pubmed.ncbi.nlm.nih.gov/36444430/
3. Alig, Stefan K, Shahrokh Esfahani, Mohammad, Garofalo, Andrea, Diehn, Maximilian, Alizadeh, Ash A. 2023. Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling. In Nature, 625, 778-787. doi:10.1038/s41586-023-06903-x. https://pubmed.ncbi.nlm.nih.gov/38081297/
4. Kato, Kei, Haniuda, Kei, Fukao, Saori, Kitamura, Daisuke. . B cell-intrinsic DNase1L3 is essential for the T cell-independent type II response in mice. In International immunology, 35, 275-286. doi:10.1093/intimm/dxad001. https://pubmed.ncbi.nlm.nih.gov/36689362/
5. Sun, Jiaqi, Wang, Xiyang, Shen, Qingsong, Yuan, Yufeng, Huang, Zan. 2022. DNASE1L3 inhibits hepatocellular carcinoma by delaying cell cycle progression through CDK2. In Cellular oncology (Dordrecht, Netherlands), 45, 1187-1202. doi:10.1007/s13402-022-00709-1. https://pubmed.ncbi.nlm.nih.gov/36327092/
6. Li, Bo, Ge, Yu-Zhen, Yan, Wei-Wei, Jiang, Yi-Heng, Zuo, Shi. 2022. DNASE1L3 inhibits proliferation, invasion and metastasis of hepatocellular carcinoma by interacting with β-catenin to promote its ubiquitin degradation pathway. In Cell proliferation, 55, e13273. doi:10.1111/cpr.13273. https://pubmed.ncbi.nlm.nih.gov/35748106/
智鼠故事 
